Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 7/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30713140 | 0.86 | MAPT (0.60) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31007090 | 0.86 | MAPT (0.49) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30713154 | 0.86 | MAPT (0.60) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30147290 | 0.86 | MAPT (0.49) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27171639 | 0.85 | MAPT (0.58) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29419571 | 0.82 | MAPT (0.68) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1335647 | 0.82 | MAPT (0.68) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30713084 | 0.82 | POLB (0.56) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27171630 | 0.82 | POLB (0.56) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30097896 | 0.81 | POLB (0.62) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-4707276-A2 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4499611-B1 | MALT1 MODULATORS AND USES THEREOF | RAREFIED BIOSCIENCES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | RAREFIED BIOSCIENCES, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4499611-A1 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240425480-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-12-26 | — | — | US | disclosed |
| CN-119032083-A | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240317739-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-09-26 | — | — | US | disclosed |
| EP-4349825-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG Chem, Ltd. (KR) | 2024-04-10 | — | — | EP | disclosed |
| EP-4339196-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | LG Chem, Ltd. (KR) | 2024-03-20 | — | — | EP | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| WO-2011017578-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2010112177-A1 | ACYLATED AMINOPYRIDINES AND AMINOPYRIDAZINES AS INSECTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-10-07 | — | — | WO | disclosed |
| EP-2236505-A1 | Acylated aminopyridines and pyridazines as insecticides | Bayer CropScience AG (DE) | 2010-10-06 | — | — | EP | disclosed |
| EP-2236505-A1 | Acylated aminopyridines and pyridazines as insecticides | Bayer CropScience AG (DE) | 2010-10-06 | — | — | EP | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | MAPT 4760/4885POLB 3979/4885SMN1; SMN2 1771/4885 |
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | MALT1, SQSTM1, PPP1R10 | MAPT 1525/4885POLB 4698/4885SMN1; SMN2 2034/4885 |
| US-20240425480-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | RET, MST1R, ROS1 | MAPT 4286/4885POLB 4572/4885SMN1; SMN2 4129/4885 |
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | AAAS, DDT, QDPR | MAPT 3480/4885POLB 2949/4885SMN1; SMN2 2519/4885 |
| US-20240317739-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | CDKN1A, RET, UBTF | MAPT 2721/4885POLB 3957/4885SMN1; SMN2 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.